Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting

13 Mar 2019

Abstract excerpt

OBJECTIVE: Programmed death-ligand-1 (PDL1) is a molecule involved in immune evasion in various kinds of tumors. Here, we aim to determine whether the expression of PDL1 protein is related to the response of patients to neoadjuvant therapy and survival outcome. METHODS: Immunohistochemistry (IHC) was performed on paraffin-embedded tumor samples from core needle biopsy before neoadjuvant therapy (NAT). Univariate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30866717
DOI: 10.1080/15384047.2019.1583533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant settingPMID 30866717Read ↗

Predictive Role of Peripheral Blood Lymphocyte And Cytokine Phenotypes in Patients with Operable Breast Cancer And Neoadjuvant Therapy: A Preliminary StudySemantic proximity Read ↗

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarkerSemantic proximity Read ↗

Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.Semantic proximity Read ↗

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancerSemantic proximity Read ↗

The Effects of Chemotherapeutic Drugs on PD-L1 Gene Expression in Breast Cancer Cell LinesSemantic proximity Read ↗

Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome DataSemantic proximity Read ↗

Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.Semantic proximity Read ↗

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?Semantic proximity Read ↗

Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancerSemantic proximity Read ↗

Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine modelSemantic proximity Read ↗

RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancerSemantic proximity Read ↗

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.